0–7–21 Radiation Therapy for the Treatment of Canine Oral Melanoma

Eighteen dogs with malignant melanoma of the oral cavity were treated with high-dose per fraction (0–7–21) radiation therapy. Eight hundred cGy was administered on days 0, 7, and 21 for a total dose of 2,400 cGy in 3 weeks. Of 17 dogs evaluated, 9 (53%) had a complete remission and 5 (30%) achieved a partial remission with an overall response rate of 83%. Local failure occurred in 2 of the 9 dogs where a complete response was initially observed. One dog died of intercurrent disease, and one died of metastatic disease without evidence of local recurrence. Five dogs are alive and free of disease 9 to nineteen months from the initiation of therapy. The 0–7–21 protocol was well-tolerated, and acute radiation reactions were low-grade and limited to the skin. The results of this study demonstrate that oral melanomas in dogs are responsive to radiation. 0–7–21 radiation therapy offers a viable alternative to radical excision, especially when tumor volume or location would require cosmetically or functionally debilitating surgery.     

Comparison of dogs with septic peritonitis: 1988–1993 versus 1999–2003

Objective: To describe and compare the patient population, treatment, and outcome in dogs with septic peritonitis from 2 time periods at the same institution. Design: Retrospective study. Setting: The Matthew J. Ryan Veterinary Hospital at the University of Pennsylvania. Animals: Dogs treated surgically for septic peritonitis between 1988–1993 and 1999–2003. Interventions: None. Measurements: Preoperative physical and clinicopathologic data, surgical findings, anesthetic parameters, treatment, and outcome. Main results: No significant difference in survival among dogs treated surgically for septic peritonitis between 1988 and 1993 (21/33 [64%]) and 1999–2003 (29/51 [57%]) was detected. The patient populations of the two time periods were similar. Changes in treatment between the study periods reflected availability of new antibiotics and synthetic colloids, as well as greater attention to pain management and ulcer prevention. Duration of hospitalization was not significantly different between the two time periods, but the daily cost adjusted to 2005 dollars was higher in 1999–2003. Potential prognostic indicators were compared between survivors and non‐survivors after combining the data from both time periods, and although several parameters reached statistical significance, of greatest clinical significance were the higher blood pressure and preoperative serum albumin in survivors. Conclusions: Although new treatments were added to the supportive care of dogs with septic peritonitis, survival did not change sufficiently to detect a significant difference between the time periods evaluated. Identifying reliable prognostic indicators for septic peritonitis remains a challenge, but hypotension and decreased preoperative serum albumin were associated with non‐survival in this group of dogs.     

Canine obesity – an overview

Canine patients are generally regarded as being clinically obese when their body weight is at least 15% above ideal. The incidence of obesity in dogs is thought to be in the range of 20–40% of the general population and, since obesity is known to predispose or exacerbate a range of serious medical conditions, its importance cannot be overstated. Management of obesity through dietary restriction and increased exercise is often difficult to achieve and dependent upon owner compliance. Until recently there has been no authorized therapeutic medication available for weight reduction in dogs, and drugs used in people have proved unsuitable. However, with the development of microsomal triglyceride transfer protein inhibitors for canine use, such as dirlotapide, the veterinarian has a novel method with which to augment traditional weight control programmes. This approach has the additional advantage that weight loss is achieved without dietary restriction or change in exercise regimen, providing encouragement for the owner to comply with subsequent dietary and exercise recommendations, thereby increasing the likelihood for long-term success.     

0–7–21 Radiation Therapy for the Palliation of Advanced Cancer in Dogs

The 0–7–21 radiation therapy protocol was investigated as a palliative treatment in dogs with advanced malignancies. Twenty-four dogs with a variety of tumor types were irradiated using 800 cGy fractions given on days 0, 7, and 21. Twenty-three dogs were evaluated. Palliative response was assessed using a quality of life instrument developed for veterinary use. This pain score was based on owner response to questions regarding analgesic requirement, activity level, appetite, and degree of lameness in the affected dogs. Seventeen (74%) of the 23 dogs experienced complete pain relief, and 3 (13%) obtained partial relief. Of the 17 dogs that achieved a complete response, pain recurred in 8 at a median time of 70 days. Six dogs were alive and free of pain up to 557 days after irradiation. The 0–7–21 protocol was well tolerated; pain relief occurred quickly, and acute radiation reactions were negligible.